Accounts Payable - Skye Bioscience Inc (NASDAQ:SKYE) - Alpha Spread

Skye Bioscience Inc
NASDAQ:SKYE

Watchlist Manager
Skye Bioscience Inc Logo
Skye Bioscience Inc
NASDAQ:SKYE
Watchlist
Price: 5.49 USD 4.77% Market Closed
Market Cap: 154.1m USD
Have any thoughts about
Skye Bioscience Inc?
Write Note

Skye Bioscience Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Skye Bioscience Inc
Accounts Payable Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Skye Bioscience Inc
NASDAQ:SKYE
Accounts Payable
$1.1m
CAGR 3-Years
39%
CAGR 5-Years
73%
CAGR 10-Years
60%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$29.3B
CAGR 3-Years
12%
CAGR 5-Years
21%
CAGR 10-Years
17%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
$537m
CAGR 3-Years
-4%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$2.3B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$327.9m
CAGR 3-Years
37%
CAGR 5-Years
34%
CAGR 10-Years
20%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$561.7m
CAGR 3-Years
6%
CAGR 5-Years
18%
CAGR 10-Years
28%

See Also

What is Skye Bioscience Inc's Accounts Payable?
Accounts Payable
1.1m USD

Based on the financial report for Jun 30, 2024, Skye Bioscience Inc's Accounts Payable amounts to 1.1m USD.

What is Skye Bioscience Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
60%

Over the last year, the Accounts Payable growth was -35%. The average annual Accounts Payable growth rates for Skye Bioscience Inc have been 39% over the past three years , 73% over the past five years , and 60% over the past ten years .

Back to Top